Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI306 Phase 3 in Hypercholesterolemia
CTR20210062Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in hypercholesterolemia, coronary arteriosclerosis, sponsored by Innovent Biologics. Started Jan 2021; status: completed.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemiacoronary arteriosclerosis
Beyond the preview
Go deeper on CTR20210062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210062.